DRG Epidemiology's coverage of renal comprises epidemiological estimates of key patient populations across 7 mature markets worldwide. We report the prevalence of renal for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the mature pharmaceutical markets of the United States, Europe, and Japan.,

DRG Epidemiology's renal anemia forecast will answer the following questions:

  • Of all people with renal anemia, how many in each country across the mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with renal anemia, how many in each country across the mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal anemia over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Note: cCoverage may vary by country and region.

Table of contents

  • Renal Anemia - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
        • Overview
          • Total Prevalence of Renal Anemia per 1000 People Aged 20+ in 2016 and 2036
          • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Renal Anemia Over the Next Ten Years
          • Analysis of the Total Prevalent Cases of Renal Anemia in 2016 by Dialysis
      • Epidemiology Data
      • Methods
        • Total Prevalent Cases of Renal Anemia
        • Total Prevalent Cases of Renal Anemia by Dialysis
        • Diagnosed Prevalent Cases of Renal Anemia
        • Drug-Treated Prevalent Cases of Renal Anemia
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Renal Anemia
          • Studies Excluded from the Analysis of Renal Anemai
        • Risk/Protective Factors
          • Risk/Protective Factors for Renal Anemia
        • Bibliography

    Author(s): Seth Kuranz, MPH

    Seth joined DRG as an Associate Epidemiologist in 2015. 

    Seth holds an M.P.H. from Boston University and a B.A. in Anthropology from Arizona State University.  Currently Seth is pursuing a doctorate in Epidemiology from Boston University School of Public Health.  Prior to joining DRG, Seth served as the coordinator of a community coalition implementing substance abuse prevention initiatives.  For the past three years Seth worked as a research assistant examining misuse of alcohol among University students in Mexico City contributing to data analysis and publication of the research findings.   

     


    Related Reports

    Renal Anemia - Landscape & Forecast - Disease Landscape & Forecast

    Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their limitati...

    View Details

    Renal Anemia - Access & Reimbursement - Detailed, Expanded Analysis (US) 2020

    This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U...

    View Details

    Renal Anemia - Current Treatment - Detailed, Expanded Analysis (US)

    Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist, physicians, patients, and healthcare systems have concerns about their limitations. Delivery...

    View Details